Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Community Projects (beta) QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:3alpha-hydroxy steroid
go back to main search page
Accession:CHEBI:36835 term browser browse the term
Definition:A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
Synonyms:related_synonym: 3alpha-hydroxy steroids;   3alpha-hydroxysteroid;   3alpha-hydroxysteroids;   Formula=C19H31OR;   SMILES=C12C(C3C(C(CC3)*)(C)CC1)CCC4C2(CC[C@H](C4)O)C;   a 3alpha-hydroxysteroid
 alt_id: CHEBI:71194
 xref: MetaCyc:3-alpha-Hydroxysteroids;   PMID:11514561


show annotations for term's descendants           Sort by:
3alpha-hydroxy-5beta-androstan-17-one term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions
increases chemical synthesis		 ISO [AKR1D1 protein alternative form results in increased metabolism of androstane-3,17-dione] which results in increased chemical synthesis of Etiocholanolone; [AKR1D1 protein alternative form results in increased reduction of Androstenedione] which results in increased chemical synthesis of Etiocholanolone; [AKR1D1 protein results in increased metabolism of androstane-3,17-dione] which results in increased chemical synthesis of Etiocholanolone; [AKR1D1 protein results in increased reduction of Androstenedione] which results in increased chemical synthesis of Etiocholanolone
AKR1D1 protein alternative form results in increased chemical synthesis of Etiocholanolone; AKR1D1 protein results in increased chemical synthesis of Etiocholanolone		 CTD PMID:30928400 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Ugt2b UDP glycosyltransferase 2 family, polypeptide B increases glucuronidation EXP UGT2B protein results in increased glucuronidation of Etiocholanolone CTD PMID:2429951 NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776 		JBrowse link
3alpha-hydroxy-5beta-pregnan-20-one term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1c1 aldo-keto reductase family 1, member C1 increases reduction
affects metabolic processing		 ISO AKR1C1 protein results in increased reduction of Pregnanolone
AKR1C1 protein affects the metabolism of Pregnanolone		 CTD PMID:11995921 PMID:12604236 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases reduction
affects metabolic processing		 ISO AKR1C2 protein results in increased reduction of Pregnanolone
AKR1C2 protein affects the metabolism of Pregnanolone		 CTD PMID:11995921 PMID:12604236 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases chemical synthesis ISO AKR1C3 protein results in increased chemical synthesis of Pregnanolone CTD PMID:25463305 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Crh corticotropin releasing hormone affects expression
multiple interactions		 EXP Pregnanolone affects the expression of CRH mRNA
Pregnanolone inhibits the reaction [Methoxamine results in increased secretion of CRH protein]		 CTD PMID:7816204 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 increases hydroxylation ISO CYP17A1 protein results in increased hydroxylation of Pregnanolone analog CTD PMID:14522586 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573 		JBrowse link
G Egr2 early growth response 2 increases expression EXP Pregnanolone results in increased expression of EGR2 mRNA; Pregnanolone results in increased expression of EGR2 protein CTD PMID:17478888 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562 		JBrowse link
G Gabra1 gamma-aminobutyric acid type A receptor subunit alpha 1 multiple interactions ISO Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB2 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB3 binds to GABRG2 protein alternative form] CTD PMID:29038840 NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864 		JBrowse link
G Gabra2 gamma-aminobutyric acid type A receptor subunit alpha 2 multiple interactions ISO Pregnanolone results in increased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form] CTD PMID:29038840 NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944 		JBrowse link
G Gabra4 gamma-aminobutyric acid type A receptor subunit alpha 4 increases expression
multiple interactions		 EXP
ISO		 Pregnanolone deficiency results in increased expression of GABRA4 mRNA; Pregnanolone deficiency results in increased expression of GABRA4 protein
Pregnanolone results in increased activity of [GABRA4 protein binds to GABRB3 binds to GABRD protein]		 CTD PMID:9651210 PMID:29038840 NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844 		JBrowse link
G Gabra6 gamma-aminobutyric acid type A receptor subunit alpha6 increases response to substance
multiple interactions		 ISO GABRA6 protein results in increased susceptibility to Pregnanolone
Pregnanolone results in increased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]		 CTD PMID:9281599 PMID:29038840 NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769 		JBrowse link
G Gabrb1 gamma-aminobutyric acid type A receptor subunit beta1 multiple interactions ISO Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form] CTD PMID:29038840 NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948 		JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 multiple interactions ISO Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB2 binds to GABRG2 protein alternative form] CTD PMID:29038840 NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 multiple interactions ISO Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA4 protein binds to GABRB3 binds to GABRD protein]; Pregnanolone results in increased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form] CTD PMID:29038840 NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961 		JBrowse link
G Gabrd gamma-aminobutyric acid type A receptor subunit delta decreases expression
multiple interactions		 EXP
ISO		 Pregnanolone results in decreased expression of GABRD protein
Pregnanolone results in increased activity of [GABRA4 protein binds to GABRB3 binds to GABRD protein]		 CTD PMID:16914187 PMID:29038840 NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411 		JBrowse link
G Gabre gamma-aminobutyric acid type A receptor subunit epsilon decreases response to substance EXP GABRE protein results in decreased susceptibility to Pregnanolone CTD PMID:9039914 NCBI chr  X:150,060,035...150,078,773
Ensembl chr  X:150,060,040...150,078,693 		JBrowse link
G Gabrg2 gamma-aminobutyric acid type A receptor subunit gamma 2 multiple interactions ISO Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB2 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA1 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Pregnanolone results in increased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form] CTD PMID:29038840 NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression EXP Pregnanolone results in decreased expression of GSK3B protein CTD PMID:17443805 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 multiple interactions ISO [Pregnanolone co-treated with NAD] binds to HSD17B10 protein CTD PMID:25526675 NCBI chr  X:21,089,142...21,091,603
Ensembl chr  X:21,089,122...21,109,488 		JBrowse link
G Il1b interleukin 1 beta decreases response to substance ISO Pregnanolone results in decreased susceptibility to IL1B protein CTD PMID:19458216 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Mag myelin-associated glycoprotein increases expression EXP Pregnanolone results in increased expression of MAG mRNA CTD PMID:16787508 NCBI chr 1:86,148,227...86,163,726
Ensembl chr 1:86,148,228...86,163,656 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Pregnanolone results in decreased phosphorylation of and results in decreased activity of MAPK1 protein CTD PMID:16581232 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapt microtubule-associated protein tau increases phosphorylation
decreases expression		 EXP Pregnanolone results in increased phosphorylation of MAPT protein
Pregnanolone results in decreased expression of MAPT protein		 CTD PMID:17443805 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Mpz myelin protein zero increases expression EXP Pregnanolone results in increased expression of MPZ mRNA CTD PMID:16787508 NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
increases activity		 ISO Pregnanolone metabolite inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
Pregnanolone metabolite results in increased activity of NR1H4 protein		 CTD PMID:22961653 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions ISO Pregnanolone analog inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; Pregnanolone inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein] CTD PMID:16581232 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375 		JBrowse link
G Penk proenkephalin increases expression EXP Pregnanolone results in increased expression of PENK mRNA CTD PMID:19458216 NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129 		JBrowse link
G Pmp22 peripheral myelin protein 22 increases expression EXP Pregnanolone results in increased expression of PMP22 mRNA CTD PMID:16787508 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714 		JBrowse link
G Prkca protein kinase C, alpha decreases expression ISO Pregnanolone results in decreased expression of PRKCA protein CTD PMID:16581232 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012 		JBrowse link
G Slc1a1 solute carrier family 1 member 1 multiple interactions EXP Pregnanolone results in increased localization of and results in increased activity of SLC1A1 protein CTD PMID:21688266 NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402 		JBrowse link
G Srd5a1 steroid 5 alpha-reductase 1 increases chemical synthesis ISO SRD5A1 protein results in increased chemical synthesis of Pregnanolone CTD PMID:25463305 NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461 		JBrowse link
5alpha-androst-16-en-3alpha-ol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA; [Endosulfan inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA CTD PMID:20361990 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 decreases activity
multiple interactions		 ISO androst-16-en-3-ol results in decreased activity of NR1I3 protein
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]; [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA; [Endosulfan inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA		 CTD PMID:20361990 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
5alpha-androstane-3alpha,17beta-diol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Esr2 estrogen receptor 2 affects binding EXP 3alpha-androstanediol binds to Esr2 protein RGD PMID:9048584 RGD:8694130 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
7-oxolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases reduction
multiple interactions		 ISO HSD11B1 protein results in increased reduction of 7-ketolithocholic acid
[HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid; [HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Ursodeoxycholic Acid		 CTD PMID:21453287 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
androsterone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor affects binding EXP Androsterone binds to AR protein CTD PMID:14565775 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 affects chemical synthesis ISO CYP17A1 protein affects the chemical synthesis of Androsterone CTD PMID:14522586 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 increases reduction ISO DHRS11 protein results in increased reduction of Androsterone CTD PMID:30926317 NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases activity EXP Androsterone results in decreased activity of G6PD protein CTD PMID:7752092 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 increases metabolic processing ISO HSD17B12 protein results in increased metabolism of Androsterone CTD PMID:17641292 NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Androsterone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO Androsterone inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Diethylstilbestrol] CTD PMID:23126256 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 multiple interactions ISO Androsterone inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Androsterone inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Hymecromone] CTD PMID:33290829 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 increases glucuronidation ISO UGT1A4 protein SNP results in increased glucuronidation of Androsterone analog CTD PMID:15708967 NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt2b UDP glycosyltransferase 2 family, polypeptide B increases glucuronidation EXP UGT2B protein results in increased glucuronidation of Androsterone CTD PMID:2429951 NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776 		JBrowse link
G Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 increases metabolic processing ISO UGT2B17 protein results in increased metabolism of Androsterone CTD PMID:8798464 NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation
decreases activity
multiple interactions		 ISO UGT2B7 protein results in increased glucuronidation of Androsterone
Androsterone results in decreased activity of UGT2B7 protein
Androsterone inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Androsterone inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Diethylstilbestrol]; Androsterone inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Hymecromone]		 CTD PMID:11186130 PMID:23126256 PMID:26875642 PMID:33290829 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
androsterone 3-glucosiduronic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kl Klotho multiple interactions ISO androsterone glucuronide inhibits the reaction [KL protein results in increased hydrolysis of Glucuronides] CTD PMID:14701853 NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080 		JBrowse link
brassinolide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator decreases expression ISO brassinolide results in decreased expression of BCL2 protein CTD PMID:17557751 PMID:20833159 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO brassinolide results in decreased expression of BCL2L1 protein CTD PMID:20833159 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bid BH3 interacting domain death agonist decreases expression ISO brassinolide results in decreased expression of BID protein CTD PMID:20833159 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Casp3 caspase 3 increases activity
increases expression		 ISO brassinolide results in increased activity of CASP3 protein
brassinolide results in increased expression of CASP3 protein modified form		 CTD PMID:17557751 PMID:20833159 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO brassinolide results in decreased expression of CCNB1 protein CTD PMID:20833159 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO brassinolide results in decreased expression of CCND1 protein CTD PMID:20833159 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 decreases expression ISO brassinolide results in decreased expression of CCNE1 protein CTD PMID:20833159 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO brassinolide results in decreased expression of CDK2 protein CTD PMID:20833159 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO brassinolide results in decreased expression of CDK4 protein CTD PMID:20833159 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO brassinolide results in increased expression of CDKN1A protein CTD PMID:20833159 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B decreases expression ISO brassinolide results in decreased expression of CDKN1B protein CTD PMID:20833159 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Esr1 estrogen receptor 1 decreases expression ISO brassinolide results in decreased expression of ESR1 CTD PMID:20833159 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 affects localization
decreases expression		 ISO brassinolide affects the localization of ESR2 protein
brassinolide results in decreased expression of ESR2		 CTD PMID:20833159 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Mdm2 MDM2 proto-oncogene decreases expression ISO brassinolide results in decreased expression of MDM2 protein CTD PMID:20833159 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression ISO brassinolide results in decreased expression of RB1 protein; brassinolide results in decreased expression of RB1 protein modified form CTD PMID:20833159 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Tp53 tumor protein p53 increases expression ISO brassinolide results in increased expression of TP53 protein CTD PMID:20833159 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
cholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression
multiple interactions		 ISO
EXP		 Cholic Acid results in increased expression of ABCA1 mRNA
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCA1 mRNA		 CTD PMID:14684380 PMID:15694933 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Abca8 ATP binding cassette subfamily A member 8 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA CTD PMID:30996006 NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988 		JBrowse link
G Abca9 ATP binding cassette subfamily A member 9 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA CTD PMID:30996006 NCBI chr10:95,077,615...95,137,751
Ensembl chr10:95,079,058...95,139,608 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
decreases activity
multiple interactions		 EXP
ISO		 Cholic Acid results in increased expression of ABCB11 mRNA
Cholic Acid results in increased expression of ABCB11 mRNA; Cholic Acid results in increased expression of ABCB11 protein
Cholic Acid results in decreased activity of ABCB11 protein
Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB11 mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCB11 mRNA		 CTD PMID:11438506 PMID:12971955 PMID:14684380 PMID:15466244 PMID:15694933 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression ISO Cholic Acid results in increased expression of ABCB1A mRNA; Cholic Acid results in increased expression of ABCB1A protein CTD PMID:11438506 PMID:17521389 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb1b ATP-binding cassette, sub-family B member 1B increases expression ISO Cholic Acid results in increased expression of ABCB1B mRNA; Cholic Acid results in increased expression of ABCB1B protein CTD PMID:11438506 NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 affects secretion
increases expression
multiple interactions		 ISO ABCB4 affects the secretion of Cholic Acid
Cholic Acid results in increased expression of ABCB4 mRNA
epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB4 mRNA]		 CTD PMID:12967592 PMID:22961653 PMID:25582706 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Cholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Cholic Acid results in increased expression of ABCC2 mRNA
Cholic Acid results in increased expression of ABCC2 mRNA; Cholic Acid results in increased expression of ABCC2 protein		 CTD PMID:11438506 PMID:12971955 PMID:15694933 PMID:25055961 PMID:25582706 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression ISO Cholic Acid results in increased expression of ABCC3 mRNA CTD PMID:12971955 PMID:25055961 PMID:25582706 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA CTD PMID:30996006 NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of ABCG5 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA		 CTD PMID:25055961 PMID:25582706 PMID:30996006 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of ABCG8 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA		 CTD PMID:25582706 PMID:30996006 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein] CTD PMID:35622622 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
increases abundance		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Cholic Acid]
AHR gene mutant form results in increased secretion of Cholic Acid
AHR gene mutant form results in increased abundance of Cholic Acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G AKR1C3l1 aldo-keto reductase family 1 member C3-like 1 increases abundance EXP AKR1C4 protein results in increased abundance of Cholic Acid CTD PMID:3468121 NCBI chr17:65,847,580...65,881,488
Ensembl chr17:65,835,634...65,881,488 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein; Diethylnitrosamine inhibits the reaction [Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein] CTD PMID:27151938 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA CTD PMID:30996006 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholic Acid inhibits the reaction [Diethylnitrosamine results in increased cleavage of CASP3 protein] CTD PMID:27151938 PMID:35622622 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein] CTD PMID:16933029 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression		 ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of CCND1 protein
Cholic Acid results in increased expression of CCND1 protein		 CTD PMID:27151938 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein] CTD PMID:35622622 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression
multiple interactions		 ISO Cholic Acid results in decreased expression of CDKN1A protein
[Diethylnitrosamine co-treated with Cholic Acid] results in decreased expression of CDKN1A protein		 CTD PMID:27151938 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Chek1 checkpoint kinase 1 increases expression ISO Cholic Acid results in increased expression of CHEK1 protein CTD PMID:20025956 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009 		JBrowse link
G Chrm2 cholinergic receptor, muscarinic 2 increases expression EXP Cholic Acid results in increased expression of CHRM2 mRNA CTD PMID:35584729 NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103 		JBrowse link
G Cldn1 claudin 1 decreases expression EXP Cholic Acid results in decreased expression of CLDN1 mRNA; Cholic Acid results in decreased expression of CLDN1 protein CTD PMID:35584729 NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724 		JBrowse link
G Cldn2 claudin 2 decreases expression EXP Cholic Acid results in decreased expression of CLDN2 mRNA; Cholic Acid results in decreased expression of CLDN2 protein CTD PMID:35584729 NCBI chr  X:103,459,870...103,473,794
Ensembl chr  X:103,459,780...103,474,838 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP
ISO		 Cholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767 PMID:25582706 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Cholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression ISO Cholic Acid results in increased expression of CYP2A4 mRNA CTD PMID:17521389 NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 increases expression ISO Cholic Acid results in increased expression of CYP2B10 mRNA CTD PMID:17521389 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052 		JBrowse link
G Cyp2b2 cytochrome P450, family 2, subfamily b, polypeptide 2 increases expression ISO Cholic Acid results in increased expression of CYP2B13 mRNA CTD PMID:17521389 NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO Cholic Acid results in increased expression of CYP2B9 mRNA CTD PMID:17521389 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP Cholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity
multiple interactions		 EXP
ISO		 Cholic Acid results in decreased activity of CYP3A2 protein
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid
Cholic Acid metabolite results in decreased activity of CYP3A4 protein
Cholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]		 CTD PMID:8889968 PMID:19299527 PMID:27871908 PMID:34461081 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid CTD PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression		 EXP
ISO		 [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CYP7A1 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CYP7A1 mRNA
Cholic Acid results in decreased expression of CYP7A1 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA		 CTD PMID:12072388 PMID:14684380 PMID:15694933 PMID:17521389 PMID:20671298 More... NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression ISO Cholic Acid results in decreased expression of CYP7B1 mRNA CTD PMID:20671298 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 decreases expression ISO Cholic Acid results in decreased expression of CYP8B1 mRNA CTD PMID:17521389 PMID:25055961 PMID:25582706 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein] CTD PMID:35622622 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression ISO
EXP		 Cholic Acid results in increased expression of FABP6 mRNA CTD PMID:25582706 PMID:35584729 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression		 ISO [[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Cholic Acid results in increased expression of FGF15 mRNA
Cholic Acid results in increased expression of FGF19 mRNA		 CTD PMID:22561792 PMID:25055961 PMID:25582706 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fmo3 flavin containing dimethylaniline monoxygenase 3 increases expression ISO Cholic Acid results in increased expression of FMO3 mRNA CTD PMID:17521389 NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028 		JBrowse link
G Fmo4 flavin containing dimethylaniline monoxygenase 4 increases expression ISO Cholic Acid results in increased expression of FMO4 mRNA CTD PMID:17521389 NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression ISO Cholic Acid results in increased expression of FOSL1 protein CTD PMID:20025956 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression		 ISO Cholic Acid binds to and results in increased activity of GPBAR1 protein
Cholic Acid results in increased expression of GPBAR1 mRNA		 CTD PMID:18180267 PMID:25055961 NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP Cholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] CTD PMID:3783048 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression ISO Cholic Acid results in increased expression of GSTA2 mRNA CTD PMID:17521389 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798 		JBrowse link
G Gsta3 glutathione S-transferase alpha 3 multiple interactions EXP Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] CTD PMID:3783048 NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions EXP Cholic Acid binds to and results in decreased activity of GSTA4 protein CTD PMID:3954743 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions EXP Cholic Acid binds to and results in decreased activity of GSTM1 protein CTD PMID:3954743 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions
increases expression		 EXP
ISO		 Cholic Acid binds to and results in decreased activity of GSTM2 protein
Cholic Acid results in increased expression of GSTM2 mRNA		 CTD PMID:3954743 PMID:17521389 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression ISO Cholic Acid results in increased expression of GSTM3 mRNA CTD PMID:17521389 NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553 		JBrowse link
G Hells helicase, lymphoid specific increases expression ISO Cholic Acid results in increased expression of HELLS protein CTD PMID:20025956 NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein] CTD PMID:30273964 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] CTD PMID:30273964 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Cholic Acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of IL1B mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA] CTD PMID:12072388 PMID:27151938 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO Cholic Acid results in increased expression of IL1RL1 protein CTD PMID:20025956 NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256 		JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] CTD PMID:30273964 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA] CTD PMID:30273964 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] CTD PMID:14684380 PMID:30273964 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Lrp2 LDL receptor related protein 2 increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]		 CTD PMID:15375181 NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Cholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases activity		 ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK1 protein
Cholic Acid results in increased activity of MAPK1 protein		 CTD PMID:27151938 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases activity		 ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK3 protein
Cholic Acid results in increased activity of MAPK3 protein		 CTD PMID:27151938 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression ISO Cholic Acid results in increased expression of MCM3 protein CTD PMID:20025956 NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314 		JBrowse link
G Mgst3 microsomal glutathione S-transferase 3 increases expression ISO Cholic Acid results in increased expression of MGST3 mRNA CTD PMID:17521389 NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411 		JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming decreases expression EXP Cholic Acid results in decreased expression of MUC2 mRNA CTD PMID:35584729 NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756 		JBrowse link
G Myl9 myosin light chain 9 increases phosphorylation EXP Cholic Acid results in increased phosphorylation of MYL9 protein CTD PMID:35584729 NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression ISO Cholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:25582706 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation
multiple interactions		 ISO Cholic Acid results in increased phosphorylation of NFKBIA protein
Cholic Acid promotes the reaction [Diethylnitrosamine results in increased phosphorylation of NFKBIA protein]		 CTD PMID:27151938 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Cholic Acid results in increased expression of NQO1 mRNA CTD PMID:25582706 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions
increases expression		 EXP
ISO		 [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR0B2 mRNA
Cholic Acid results in increased expression of NR0B2 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]		 CTD PMID:12072388 PMID:14684380 PMID:15694933 PMID:16002565 PMID:16269825 More... NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions EXP [Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H3 protein CTD PMID:14684380 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 affects binding
decreases expression
increases phosphorylation
increases expression
multiple interactions
increases activity		 ISO
EXP		 Cholic Acid binds to NR1H4 protein
Cholic Acid results in decreased expression of NR1H4 mRNA
Cholic Acid results in increased phosphorylation of NR1H4 protein
Cholic Acid results in increased expression of NR1H4 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA; Cholic Acid binds to and results in increased activity of NR1H4 protein; Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]; Cholic Acid results in increased phosphorylation of and results in increased activity of NR1H4 protein; NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]; NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]; NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]
[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; Cholic Acid analog binds to and results in increased activity of NR1H4 protein; Cholic Acid binds to and results in increased activity of NR1H4 protein
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H4 protein		 CTD PMID:13130122 PMID:14684380 PMID:15375181 PMID:15694933 PMID:19965603 More... NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression
increases activity		 ISO Cholic Acid results in increased expression of NR1I2 mRNA
Cholic Acid metabolite results in increased activity of NR1I2 protein; Cholic Acid results in increased activity of NR1I2 protein		 CTD PMID:25582706 PMID:27871908 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Cholic Acid results in increased expression of ORM1 protein CTD PMID:20025956 NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154 		JBrowse link
G Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 increases expression ISO Cholic Acid results in increased expression of PAPSS2 mRNA CTD PMID:17521389 NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331 		JBrowse link
G Pcna proliferating cell nuclear antigen increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of PCNA protein
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of PCNA protein		 CTD PMID:27151938 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO Cholic Acid results in increased expression of PIK3R5 protein CTD PMID:20025956 NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374 		JBrowse link
G Pon1 paraoxonase 1 decreases expression
multiple interactions		 ISO
EXP		 Cholic Acid results in decreased expression of PON1 mRNA; Cholic Acid results in decreased expression of PON1 protein
[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]		 CTD PMID:16269825 PMID:30273964 NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360 		JBrowse link
G Por cytochrome p450 oxidoreductase increases expression
decreases abundance		 ISO Cholic Acid results in increased expression of POR mRNA
POR gene mutant form results in decreased abundance of Cholic Acid		 CTD PMID:17521389 PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Cholic Acid CTD PMID:29175453 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Cholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889 		JBrowse link
G Reg3b regenerating family member 3 beta decreases expression EXP Cholic Acid results in decreased expression of REG3B mRNA CTD PMID:35584729 NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015 		JBrowse link
G Reg3g regenerating family member 3 gamma decreases expression EXP Cholic Acid results in decreased expression of REG3G mRNA CTD PMID:35584729 NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Cholic Acid promotes the reaction [Diethylnitrosamine results in increased expression of RELA protein] CTD PMID:27151938 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rif1 replication timing regulatory factor 1 increases expression ISO Cholic Acid results in increased expression of RIF1 protein CTD PMID:20025956 NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA CTD PMID:22540009 PMID:30996006 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
decreases expression		 ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA
Cholic Acid results in decreased expression of SLC10A1 mRNA; Cholic Acid results in decreased expression of SLC10A1 protein		 CTD PMID:11438506 PMID:16002565 PMID:17521389 PMID:22540009 PMID:25055961 More... NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 decreases expression
affects expression		 ISO
EXP		 Cholic Acid results in decreased expression of SLC10A2 mRNA
Cholic Acid affects the expression of SLC10A2 mRNA
Cholic Acid results in decreased expression of SLC10A2 protein		 CTD PMID:25582706 PMID:35584729 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc22a20 solute carrier family 22 member 20 increases expression ISO Cholic Acid results in increased expression of SLC22A20 mRNA CTD PMID:17521389 NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822 		JBrowse link
G Slc27a5 solute carrier family 27 member 5 multiple interactions ISO Cholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Cholic Acid results in increased expression of SLC2A1 protein CTD PMID:20025956 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416 		JBrowse link
G Slc51a solute carrier family 51 member A increases expression ISO Cholic Acid results in increased expression of SLC51A mRNA CTD PMID:25055961 PMID:25582706 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions
increases expression		 ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA
Cholic Acid results in increased expression of SLC51B mRNA		 CTD PMID:22540009 PMID:22961653 PMID:25055961 PMID:25582706 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO Cholic Acid results in increased expression of SLCO1A4 mRNA CTD PMID:17521389 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 increases uptake
increases expression		 ISO SLCO1B2 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B2 mRNA		 CTD PMID:16534140 PMID:20949553 PMID:25055961 PMID:25582706 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions
increases uptake		 ISO Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Cholic Acid] CTD PMID:24285294 NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353 		JBrowse link
G Sod3 superoxide dismutase 3 multiple interactions
increases expression		 ISO NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA] CTD PMID:25496033 NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990 		JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Cholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein] CTD PMID:29968724 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stmn1 stathmin 1 increases expression ISO Cholic Acid results in increased expression of STMN1 protein CTD PMID:20025956 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation
increases expression		 ISO SULT2A1 protein results in increased sulfation of Cholic Acid
Cholic Acid results in increased expression of SULT2A1 mRNA		 CTD PMID:17521389 PMID:20102295 PMID:22961653 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfrc transferrin receptor increases expression ISO Cholic Acid results in increased expression of TFRC protein CTD PMID:20025956 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of TNF mRNA
Diethylnitrosamine promotes the reaction [Cholic Acid results in increased expression of TNF mRNA]		 CTD PMID:27151938 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vdr vitamin D receptor increases localization ISO Cholic Acid results in increased localization of VDR protein CTD PMID:20371703 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Cholic Acid results in increased expression of VEGFA protein CTD PMID:20025956 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
fusidic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity
multiple interactions		 EXP
ISO		 Fusidic Acid results in decreased activity of ABCB11 protein
Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]		 CTD PMID:12106615 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27676153 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO Fusidic Acid inhibits the reaction [ABCB1 protein results in increased export of Digoxin] CTD PMID:26888941 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions EXP Fusidic Acid results in decreased expression of and results in decreased activity of ABCC2 protein CTD PMID:12106615 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO Fusidic Acid inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam] CTD PMID:26888941 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid] CTD PMID:27676153 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 multiple interactions EXP Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] CTD PMID:26888941 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions
decreases activity		 EXP
ISO		 Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium]
Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium]
Fusidic Acid results in decreased activity of SLCO1B3 protein		 CTD PMID:26888941 PMID:27676153 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO Fusidic Acid inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol] CTD PMID:27676153 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
glycocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport
multiple interactions		 ISO ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA		 CTD PMID:15791618 PMID:32152650 PMID:33819548 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA CTD PMID:33819548 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA CTD PMID:33819548 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 PMID:33819548 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA CTD PMID:33819548 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA CTD PMID:33819548 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA CTD PMID:33819548 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Alb albumin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887 		JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA CTD PMID:33819548 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969 		JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100 		JBrowse link
G Chi3l1 chitinase 3 like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cttn cortactin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA CTD PMID:33819548 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA CTD PMID:33819548 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA CTD PMID:33819548 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c24 cytochrome P450, family 2, subfamily c, polypeptide 24 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA CTD PMID:33819548 NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238 		JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA CTD PMID:33819548 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA CTD PMID:33819548 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988 		JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344 		JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264 		JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA CTD PMID:33819548 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:66,501,848...66,509,783
Ensembl chr  X:66,501,820...66,509,925 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Gk glycerol kinase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA CTD PMID:33819548 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA CTD PMID:33819548 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA CTD PMID:33819548 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA CTD PMID:33819548 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hpx hemopexin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA CTD PMID:33819548 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA CTD PMID:33819548 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA CTD PMID:33819548 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kynu kynureninase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488 		JBrowse link
G Lbp lipopolysaccharide binding protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mmut methylmalonyl-CoA mutase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Nfxl1 nuclear transcription factor, X-box binding-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA CTD PMID:33819548 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA CTD PMID:33819548 NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions		 ISO Glycocholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA		 CTD PMID:17567710 PMID:32152650 PMID:33819548 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Pah phenylalanine hydroxylase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612 		JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583 		JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA CTD PMID:33819548 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Prkd3 protein kinase D3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443 		JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA CTD PMID:33819548 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Reep5 receptor accessory protein 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA CTD PMID:33819548 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Sdc2 syndecan 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA CTD PMID:33819548 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA CTD PMID:33819548 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA CTD PMID:33819548 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc35b1 solute carrier family 35, member B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA CTD PMID:33819548 NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA CTD PMID:33819548 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666 PMID:32152650 PMID:33819548 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srp72 signal recognition particle 72 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880 		JBrowse link
G Tjp2 tight junction protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA CTD PMID:33819548 NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA CTD PMID:33819548 NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA CTD PMID:33819548 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA CTD PMID:33819548 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519 		JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
hyodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases secretion ISO AHR gene mutant form results in increased secretion of hyodeoxycholic acid CTD PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions EXP [CYP2D6 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of hyodeoxycholic acid CTD PMID:18039809 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [CYP3A4 protein results in increased hydroxylation of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid CTD PMID:19487251 PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of hyodeoxycholic acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation
multiple interactions
increases glycosylation
affects metabolic processing		 ISO UGT2B7 protein alternative form results in increased glucuronidation of hyodeoxycholic acid; UGT2B7 protein results in increased glucuronidation of hyodeoxycholic acid
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid
UGT2B7 protein results in increased glycosylation of hyodeoxycholic acid
UGT2B7 protein affects the metabolism of hyodeoxycholic acid		 CTD PMID:8423545 PMID:8517101 PMID:12527334 PMID:21415305 PMID:36473578 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
obeticholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin decreases expression ISO obeticholic acid results in decreased expression of A2M mRNA CTD PMID:27939613 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786 		JBrowse link
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO obeticholic acid results in decreased expression of ABCA1 mRNA CTD PMID:27939613 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
increases expression		 ISO
EXP		 obeticholic acid promotes the reaction [PRMT1 protein binds to ABCB11 promoter]
Obeticholic acid inhibits the reaction [ethanol decreases expression of Abcb11 protein in liver]
obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein]
obeticholic acid results in increased expression of ABCB11 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA]; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]		 CTD
RGD		 PMID:15644430 PMID:15911693 PMID:27255380 PMID:27939613 PMID:29660435 More... RGD:15036816 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions
increases expression		 EXP
ISO		 obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA]
obeticholic acid results in increased expression of ABCB4 mRNA		 CTD PMID:15644430 PMID:27255380 PMID:27939613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression		 EXP
ISO		 obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA]
NR1H4 promotes the reaction [obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein]
obeticholic acid results in increased expression of ABCC2 mRNA		 CTD PMID:15644430 PMID:27255380 PMID:29660435 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions EXP obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA] CTD PMID:32673658 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression ISO obeticholic acid results in decreased expression of ABCG1 mRNA CTD PMID:27939613 NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948 		JBrowse link
G Acaa1a acetyl-CoA acyltransferase 1A increases expression ISO obeticholic acid results in increased expression of ACAA1 mRNA CTD PMID:27939613 NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624 		JBrowse link
G Acaa2 acetyl-CoA acyltransferase 2 increases expression ISO obeticholic acid results in increased expression of ACAA2 mRNA CTD PMID:27939613 NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha decreases expression ISO obeticholic acid results in decreased expression of ACACA mRNA CTD PMID:27939613 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457 		JBrowse link
G Acot9 acyl-CoA thioesterase 9 increases expression ISO obeticholic acid results in increased expression of ACOT9 mRNA CTD PMID:27939613 NCBI chr  X:40,073,197...40,123,573
Ensembl chr  X:40,064,810...40,123,559 		JBrowse link
G Acox1 acyl-CoA oxidase 1 increases expression ISO obeticholic acid results in increased expression of ACOX1 mRNA CTD PMID:26655953 PMID:27939613 NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232 		JBrowse link
G Acox2 acyl-CoA oxidase 2 increases expression ISO obeticholic acid results in increased expression of ACOX2 mRNA CTD PMID:27939613 NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160 		JBrowse link
G Acox3 acyl-CoA oxidase 3, pristanoyl increases expression ISO obeticholic acid results in increased expression of ACOX3 mRNA CTD PMID:27939613 NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 decreases expression ISO obeticholic acid results in decreased expression of ACSL1 mRNA CTD PMID:27939613 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 increases expression ISO obeticholic acid results in increased expression of ACSL4 mRNA CTD PMID:27939613 NCBI chr  X:105,942,794...106,006,573
Ensembl chr  X:105,942,799...106,006,427 		JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 increases expression ISO obeticholic acid results in increased expression of ACSL5 mRNA CTD PMID:27939613 NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607 		JBrowse link
G Acsl6 acyl-CoA synthetase long-chain family member 6 increases expression ISO obeticholic acid results in increased expression of ACSL6 mRNA CTD PMID:27939613 NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757 		JBrowse link
G Adamtsl2 ADAMTS-like 2 decreases expression ISO obeticholic acid results in decreased expression of ADAMTSL2 mRNA CTD PMID:27939613 NCBI chr 3:10,397,774...10,434,557
Ensembl chr 3:10,404,626...10,434,554 		JBrowse link
G Adcy1 adenylate cyclase 1 increases expression ISO obeticholic acid results in increased expression of ADCY1 mRNA CTD PMID:27939613 NCBI chr14:81,911,240...82,020,594
Ensembl chr14:81,911,099...82,028,969 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide decreases expression ISO obeticholic acid results in decreased expression of ADH1C mRNA CTD PMID:27939613 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 decreases expression ISO obeticholic acid results in decreased expression of AGPAT2 mRNA CTD PMID:27939613 NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371 		JBrowse link
G Agpat5 1-acylglycerol-3-phosphate O-acyltransferase 5 decreases expression ISO obeticholic acid results in decreased expression of AGPAT5 mRNA CTD PMID:27939613 NCBI chr16:70,939,480...70,985,745
Ensembl chr16:70,943,135...70,985,560 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 decreases expression ISO obeticholic acid results in decreased expression of AKR1D1 mRNA CTD PMID:27939613 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
decreases expression		 ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of AKT1 protein]; obeticholic acid promotes the reaction [Dietary Fats results in decreased phosphorylation of AKT1 protein]
obeticholic acid results in decreased phosphorylation of AKT1 protein
obeticholic acid results in decreased expression of AKT1 mRNA		 CTD PMID:27865854 PMID:27939613 PMID:35267068 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt2 AKT serine/threonine kinase 2 decreases expression ISO obeticholic acid results in decreased expression of AKT2 mRNA CTD PMID:27939613 NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817 		JBrowse link
G Alb albumin decreases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in decreased expression of ALB mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of ALB mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of ALB protein		 CTD PMID:27939613 PMID:35267068 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Aldoa aldolase, fructose-bisphosphate A decreases expression ISO obeticholic acid results in decreased expression of ALDOA mRNA CTD PMID:27939613 NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182 		JBrowse link
G Aldob aldolase, fructose-bisphosphate B decreases expression ISO obeticholic acid results in decreased expression of ALDOB mRNA CTD PMID:27939613 NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116 		JBrowse link
G Aldoc aldolase, fructose-bisphosphate C increases expression ISO obeticholic acid results in increased expression of ALDOC mRNA CTD PMID:27939613 NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066 		JBrowse link
G Amn amnion associated transmembrane protein decreases expression ISO obeticholic acid results in decreased expression of AMN mRNA CTD PMID:27939613 NCBI chr 6:130,311,372...130,318,815
Ensembl chr 6:130,311,372...130,318,815 		JBrowse link
G Apoa1 apolipoprotein A1 decreases expression ISO obeticholic acid results in decreased expression of APOA1 mRNA CTD PMID:27939613 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apoa2 apolipoprotein A2 increases expression ISO obeticholic acid results in increased expression of APOA2 mRNA CTD PMID:27939613 NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355 		JBrowse link
G Apob apolipoprotein B increases expression ISO obeticholic acid results in increased expression of APOB mRNA CTD PMID:27939613 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497 		JBrowse link
G Apoc2 apolipoprotein C2 increases expression ISO obeticholic acid results in increased expression of APOC2 mRNA CTD PMID:27939613 NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476 		JBrowse link
G Apoc3 apolipoprotein C3 decreases expression ISO obeticholic acid results in decreased expression of APOC3 mRNA CTD PMID:27939613 NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583 		JBrowse link
G Apoe apolipoprotein E decreases expression ISO obeticholic acid results in decreased expression of APOE mRNA CTD PMID:27939613 NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932 		JBrowse link
G Aspg asparaginase decreases expression ISO obeticholic acid results in decreased expression of ASPG mRNA CTD PMID:27939613 NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268 		JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA] CTD PMID:35439472 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Bad BCL2-associated agonist of cell death decreases expression ISO obeticholic acid results in decreased expression of BAD mRNA CTD PMID:27939613 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions		 ISO obeticholic acid results in increased expression of BCL2 mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of BCL2 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bid BH3 interacting domain death agonist decreases expression ISO obeticholic acid results in decreased expression of BID mRNA CTD PMID:27939613 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO obeticholic acid results in decreased expression of BIRC3 mRNA CTD PMID:27939613 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802 		JBrowse link
G C5ar2 complement C5a receptor 2 decreases expression ISO obeticholic acid results in decreased expression of C5AR2 mRNA CTD PMID:27939613 NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517 		JBrowse link
G Car14 carbonic anhydrase 14 increases expression ISO obeticholic acid results in increased expression of CA14 mRNA CTD PMID:27939613 NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693 		JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO		 obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein]
obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of CASP3 protein]		 CTD PMID:15860571 PMID:26655953 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases expression ISO obeticholic acid results in increased expression of CASP8 mRNA CTD PMID:27939613 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CCL2 mRNA] CTD PMID:27865854 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCNB1 protein] CTD PMID:29660435 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCND1 protein] CTD PMID:29660435 PMID:35439472 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccs copper chaperone for superoxide dismutase decreases expression ISO obeticholic acid results in decreased expression of CCS mRNA CTD PMID:27939613 NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915 		JBrowse link
G Cd14 CD14 molecule decreases expression ISO obeticholic acid results in decreased expression of CD14 mRNA CTD PMID:27939613 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cldn5 claudin 5 multiple interactions ISO obeticholic acid inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein] CTD PMID:36720452 NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992 		JBrowse link
G Clic4 chloride intracellular channel 4 increases expression ISO obeticholic acid results in increased expression of CLIC4 mRNA CTD PMID:27939613 NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452 		JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions		 EXP
ISO		 obeticholic acid results in decreased expression of COL1A1 mRNA; obeticholic acid results in decreased expression of COL1A1 protein
obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]
obeticholic acid inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]		 CTD PMID:15860571 PMID:15980055 PMID:27939613 PMID:30745416 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions
increases expression		 ISO
EXP		 obeticholic acid promotes the reaction [Palmitic Acid results in increased expression of CPT1A mRNA]
obeticholic acid results in increased expression of CPT1A protein
Obeticholic acid inhibits the reaction [ethanol decreases expression of CPT1a mRNA and protein in liver]
obeticholic acid inhibits the reaction [Ethanol results in decreased expression of CPT1A protein]
obeticholic acid results in increased expression of CPT1A mRNA		 CTD
RGD		 PMID:26655953 PMID:27939613 PMID:27939985 PMID:32738331 PMID:27939985 RGD:15036816 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 increases expression ISO obeticholic acid results in increased expression of CPT2 mRNA CTD PMID:27939613 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095 		JBrowse link
G Crct1 cysteine-rich C-terminal 1 decreases expression ISO obeticholic acid results in decreased expression of CRCT1 mRNA CTD PMID:27939613 NCBI chr 2:178,633,789...178,635,274
Ensembl chr 2:178,634,092...178,634,394 		JBrowse link
G Creb3l1 cAMP responsive element binding protein 3-like 1 decreases expression ISO obeticholic acid results in decreased expression of CREB3L1 mRNA CTD PMID:27939613 NCBI chr 3:77,952,589...77,993,513
Ensembl chr 3:77,952,540...77,993,456 		JBrowse link
G Creb3l3 cAMP responsive element binding protein 3-like 3 increases expression ISO obeticholic acid results in increased expression of CREB3L3 mRNA CTD PMID:27939613 NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048 		JBrowse link
G Crp C-reactive protein decreases expression ISO obeticholic acid results in decreased expression of CRP mRNA CTD PMID:27939613 NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CXCL2 mRNA] CTD PMID:27865854 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CXCL1 mRNA] CTD PMID:27865854 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP19A1 mRNA CTD PMID:27939613 NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP1A1 mRNA CTD PMID:27939613 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions
decreases expression
decreases activity		 ISO
EXP		 obeticholic acid inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of Acetaminophen]; obeticholic acid inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin]
obeticholic acid results in decreased expression of CYP1A2 mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of CYP1A2 mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of CYP1A2 protein
obeticholic acid results in decreased activity of CYP1A2 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP27A1 mRNA CTD PMID:27939613 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases expression ISO obeticholic acid results in decreased expression of CYP2C8 mRNA CTD PMID:27939613
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases expression ISO obeticholic acid results in increased expression of CYP2D6 mRNA CTD PMID:27939613 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP2E1 mRNA CTD PMID:27939613 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp2r1 cytochrome P450, family 2, subfamily r, polypeptide 1 increases expression ISO obeticholic acid results in increased expression of CYP2R1 mRNA CTD PMID:27939613 NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759 		JBrowse link
G Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP2S1 mRNA CTD PMID:27939613 NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303 		JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO obeticholic acid results in increased expression of CYP2U1 mRNA CTD PMID:27939613 NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882 		JBrowse link
G Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP39A1 mRNA CTD PMID:27939613 NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775 		JBrowse link
G Cyp3a18 cytochrome P450, family 3, subfamily a, polypeptide 18 decreases expression ISO obeticholic acid results in decreased expression of CYP3A43 mRNA CTD PMID:27939613 NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
decreases expression
decreases activity		 ISO
EXP		 obeticholic acid inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; obeticholic acid inhibits the reaction [CYP3A4 protein results in increased metabolism of Testosterone]
obeticholic acid results in decreased expression of CYP3A2 mRNA
obeticholic acid results in decreased expression of CYP3A4 mRNA
obeticholic acid results in decreased activity of CYP3A4 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 decreases expression EXP obeticholic acid results in decreased expression of CYP3A23-3A1 mRNA CTD PMID:35267068 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 decreases expression ISO obeticholic acid results in decreased expression of CYP3A5 mRNA CTD PMID:27939613 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp4f1 cytochrome P450, family 4, subfamily f, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP4F12 mRNA CTD PMID:27939613 NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046 		JBrowse link
G Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 decreases expression ISO obeticholic acid results in decreased expression of CYP4F3 mRNA CTD PMID:27939613 NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940 		JBrowse link
G Cyp4f39 cytochrome P450, family 4, subfamily f, polypeptide 39 decreases expression ISO obeticholic acid results in decreased expression of CYP4F22 mRNA CTD PMID:27939613 NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181 		JBrowse link
G Cyp4f40 cytochrome P450, family 4, subfamily f, polypeptide 40 decreases expression ISO obeticholic acid results in decreased expression of CYP4F11 mRNA CTD PMID:27939613 NCBI chr 7:11,691,648...11,707,437
Ensembl chr 7:11,692,086...11,706,229 		JBrowse link
G Cyp51 cytochrome P450, family 51 decreases expression ISO obeticholic acid results in decreased expression of CYP51A1 mRNA CTD PMID:27939613 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in decreased expression of CYP7A1 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
Obeticholic acid inhibits the reaction [ethanol increases expression of Cyp7a1 protein in liver]
obeticholic acid decreases expression of CYP7a1 mRNA in liver in porcine serum induced model of cirrhosis in rat
obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]		 CTD
RGD		 PMID:15644430 PMID:15911693 PMID:27939613 PMID:29660435 PMID:32673658 More... RGD:15036816, RGD:15045602 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 decreases expression
multiple interactions
increases expression		 EXP
ISO		 obeticholic acid results in decreased expression of CYP8B1 mRNA
obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]
obeticholic acid results in increased expression of CYP8B1 mRNA		 CTD PMID:15644430 PMID:27939613 PMID:29660435 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of DDIT3 protein] CTD PMID:26655953 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 decreases expression ISO obeticholic acid results in decreased expression of DGAT2 mRNA CTD PMID:27939613 NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428 		JBrowse link
G Dhcr7 7-dehydrocholesterol reductase increases expression ISO obeticholic acid results in increased expression of DHCR7 mRNA CTD PMID:27939613 NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 increases expression ISO obeticholic acid results in increased expression of DNAJB11 mRNA CTD PMID:27939613 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dpyd dihydropyrimidine dehydrogenase decreases expression ISO obeticholic acid results in decreased expression of DPYD mRNA CTD PMID:27939613 NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982 		JBrowse link
G Dusp6 dual specificity phosphatase 6 increases expression ISO obeticholic acid results in increased expression of DUSP6 mRNA CTD PMID:27939613 NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185 		JBrowse link
G Ecsit ECSIT signaling integrator decreases expression ISO obeticholic acid results in decreased expression of ECSIT mRNA CTD PMID:27939613 NCBI chr 8:20,605,583...20,618,453
Ensembl chr 8:20,605,583...20,618,390 		JBrowse link
G Elovl1 ELOVL fatty acid elongase 1 increases expression ISO obeticholic acid results in increased expression of ELOVL1 mRNA CTD PMID:27939613 NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958 		JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 increases expression ISO obeticholic acid results in increased expression of ELOVL2 mRNA CTD PMID:27939613 NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848 		JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 decreases expression ISO obeticholic acid results in decreased expression of ELOVL6 mRNA CTD PMID:27939613 NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186 		JBrowse link
G Elovl7 ELOVL fatty acid elongase 7 increases expression ISO obeticholic acid results in increased expression of ELOVL7 mRNA CTD PMID:27939613 NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845 		JBrowse link
G Enc1 ectodermal-neural cortex 1 increases expression ISO obeticholic acid results in increased expression of ENC1 mRNA CTD PMID:27939613 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Eno1 enolase 1 decreases expression ISO obeticholic acid results in decreased expression of ENO1 mRNA CTD PMID:27939613 NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 		JBrowse link
G Eno3 enolase 3 increases expression ISO obeticholic acid results in increased expression of ENO3 mRNA CTD PMID:27939613 NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921 		JBrowse link
G Fabp6 fatty acid binding protein 6 multiple interactions
increases expression		 ISO NR1H4 gene mutant form inhibits the reaction [obeticholic acid results in increased expression of FABP6 mRNA] CTD PMID:22918042 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fadd Fas associated via death domain increases expression ISO obeticholic acid results in increased expression of FADD mRNA CTD PMID:27939613 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions EXP Obeticholic acid inhibits the reaction [ethanol increases expression of Fas mRNA and protein in liver] RGD PMID:27939985 RGD:15036816 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Fasn fatty acid synthase multiple interactions
decreases expression		 ISO obeticholic acid inhibits the reaction [Palmitic Acid results in increased expression of FASN mRNA]
obeticholic acid inhibits the reaction [Ethanol results in increased expression of FASN protein]
obeticholic acid results in decreased expression of FASN mRNA		 CTD PMID:26655953 PMID:27939613 PMID:27939985 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fbp1 fructose-bisphosphatase 1 decreases expression ISO obeticholic acid results in decreased expression of FBP1 mRNA CTD PMID:27939613 NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071 		JBrowse link
G Fdps farnesyl diphosphate synthase decreases expression ISO obeticholic acid results in decreased expression of FDPS mRNA CTD PMID:27939613 NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776 		JBrowse link
G Fetub fetuin B increases expression ISO obeticholic acid results in increased expression of FETUB mRNA CTD PMID:27939613 NCBI chr11:78,082,158...78,093,022
Ensembl chr11:78,082,156...78,095,135 		JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions
increases secretion		 ISO
EXP		 obeticholic acid results in increased expression of FGF15 mRNA
Obeticholic acid inhibits the reaction [ethanol decreases expression of FGF19 protein in liver and intestine]
obeticholic acid results in increased secretion of FGF19 protein
obeticholic acid results in increased expression of FGF19 mRNA
NR1H4 gene mutant form inhibits the reaction [obeticholic acid results in increased expression of FGF15 mRNA]		 CTD
RGD		 PMID:22918042 PMID:27939613 PMID:27939985 RGD:15036816 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 decreases expression ISO obeticholic acid results in decreased expression of FGFR4 mRNA CTD PMID:27939613 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242 		JBrowse link
G Fn1 fibronectin 1 decreases expression EXP obeticholic acid decreases expression of fibronectin mRNA in liver in porcine serum induced model of cirrhosis in rat RGD PMID:15980055 RGD:1625201 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression ISO obeticholic acid results in decreased expression of FOS mRNA CTD PMID:27939613 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Foxm1 forkhead box M1 multiple interactions
increases expression		 ISO NR1H4 affects the reaction [obeticholic acid results in increased expression of FOXM1 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 protein] CTD PMID:22135065 PMID:29660435 NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684 		JBrowse link
G Foxp3 forkhead box P3 increases expression ISO obeticholic acid results in increased expression of FOXP3 mRNA CTD PMID:27939613 NCBI chr  X:14,908,494...14,924,994
Ensembl chr  X:14,908,494...14,923,838 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO obeticholic acid results in decreased expression of GAPDH mRNA CTD PMID:27939613 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression ISO obeticholic acid results in increased expression of GCLM mRNA CTD PMID:26655953 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gfer growth factor, augmenter of liver regeneration multiple interactions ISO [Dietary Fats co-treated with obeticholic acid] results in decreased expression of GFER mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of GFER protein CTD PMID:35267068 NCBI chr10:13,718,489...13,721,782
Ensembl chr10:13,718,489...13,720,869 		JBrowse link
G Gk glycerol kinase decreases expression ISO obeticholic acid results in decreased expression of GK mRNA CTD PMID:27939613 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gpam glycerol-3-phosphate acyltransferase, mitochondrial decreases expression ISO obeticholic acid results in decreased expression of GPAM mRNA CTD PMID:27939613 NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639 		JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 decreases expression ISO obeticholic acid results in decreased expression of GPD1 mRNA CTD PMID:27939613 NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein]; obeticholic acid promotes the reaction [Dietary Fats results in increased expression of GPT protein] CTD PMID:35267068 PMID:36581201 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gpx1 glutathione peroxidase 1 increases expression ISO obeticholic acid results in increased expression of GPX1 mRNA CTD PMID:26655953 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024 		JBrowse link
G Gpx2 glutathione peroxidase 2 decreases expression ISO obeticholic acid results in decreased expression of GPX2 mRNA CTD PMID:27939613 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gpx3 glutathione peroxidase 3 increases expression ISO obeticholic acid results in increased expression of GPX3 mRNA CTD PMID:27939613 NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035 		JBrowse link
G Gsr glutathione-disulfide reductase increases expression ISO obeticholic acid results in increased expression of GSR mRNA CTD PMID:26655953 PMID:27939613 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases expression ISO obeticholic acid results in decreased expression of GSTP1 mRNA CTD PMID:27939613 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 increases expression ISO obeticholic acid results in increased expression of GSTT1 mRNA CTD PMID:27939613 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Gys2 glycogen synthase 2 increases expression ISO obeticholic acid results in increased expression of GYS2 mRNA CTD PMID:27939613 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228 		JBrowse link
G Hist2h2be histone cluster 2 H2B family member E decreases expression ISO obeticholic acid results in decreased expression of H2BC11 mRNA CTD PMID:27939613 NCBI chr 2:183,780,583...183,783,030 JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase decreases expression ISO obeticholic acid results in decreased expression of HMGCR mRNA CTD PMID:27939613 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression ISO obeticholic acid results in decreased expression of HMGCS1 mRNA CTD PMID:27939613 NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha decreases expression
multiple interactions		 EXP
ISO		 obeticholic acid results in decreased expression of HNF4A mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of HNF4A mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of HNF4A protein		 CTD PMID:35267068 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320 		JBrowse link
G Hras HRas proto-oncogene, GTPase decreases expression ISO obeticholic acid results in decreased expression of HRAS mRNA CTD PMID:27939613 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 decreases expression ISO obeticholic acid results in decreased expression of HSD17B7 mRNA CTD PMID:27939613 NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 decreases expression ISO obeticholic acid results in decreased expression of HSD3B7 mRNA CTD PMID:27939613 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of HSPA5 protein]; obeticholic acid inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein] CTD PMID:26655953 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspg2 heparan sulfate proteoglycan 2 decreases expression ISO obeticholic acid results in decreased expression of HSPG2 mRNA CTD PMID:27939613 NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594 		JBrowse link
G Id2 inhibitor of DNA binding 2 decreases expression ISO obeticholic acid results in decreased expression of ID2 mRNA CTD PMID:27939613 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400 		JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 decreases expression ISO obeticholic acid results in decreased expression of IDI1 mRNA CTD PMID:27939613 NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357 		JBrowse link
G Igfals insulin-like growth factor binding protein, acid labile subunit decreases expression ISO obeticholic acid results in decreased expression of IGFALS mRNA CTD PMID:27939613 NCBI chr10:13,897,468...13,903,920
Ensembl chr10:13,898,395...13,902,677 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL10 protein]; obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of IL10 protein] CTD PMID:30745416 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of IL18 mRNA] CTD PMID:35688268 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]; obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA] CTD PMID:27865854 PMID:29660435 PMID:35688268 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO obeticholic acid promotes the reaction [Carbon Tetrachloride results in increased expression of IL4 mRNA] CTD PMID:27865854 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 mRNA]; obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL6 protein]; obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of IL6 mRNA] CTD PMID:29660435 PMID:30745416 PMID:35688268 PMID:36720452 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il6r interleukin 6 receptor decreases expression ISO obeticholic acid results in decreased expression of IL6R mRNA CTD PMID:27939613 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536 		JBrowse link
G Il6st interleukin 6 cytokine family signal transducer decreases expression ISO obeticholic acid results in decreased expression of IL6ST mRNA CTD PMID:27939613 NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936 		JBrowse link
G Inhbb inhibin subunit beta B increases expression ISO obeticholic acid results in increased expression of INHBB mRNA CTD PMID:27939613 NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO obeticholic acid results in decreased expression of IRAK1 mRNA CTD PMID:27939613 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521 		JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 decreases expression ISO obeticholic acid results in decreased expression of IRAK2 mRNA CTD PMID:27939613 NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO obeticholic acid results in increased expression of JUN mRNA CTD PMID:27939613 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit decreases expression ISO obeticholic acid results in decreased expression of JUNB mRNA CTD PMID:27939613 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP NR0B2 protein affects the reaction [obeticholic acid inhibits the reaction [JUND protein binds to TIMP1 promoter]] CTD PMID:15860571 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Krt18 keratin 18 multiple interactions ISO [Dietary Fats co-treated with obeticholic acid] results in decreased expression of KRT18 mRNA CTD PMID:35267068 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 		JBrowse link
G Lbr lamin B receptor decreases expression ISO obeticholic acid results in decreased expression of LBR mRNA CTD PMID:27939613 NCBI chr13:93,539,386...93,564,026
Ensembl chr13:93,538,920...93,564,017 		JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases expression ISO obeticholic acid results in decreased expression of LCAT mRNA CTD PMID:27939613 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Ldlr low density lipoprotein receptor decreases expression ISO obeticholic acid results in decreased expression of LDLR mRNA CTD PMID:27939613 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Leng8 leukocyte receptor cluster member 8 increases expression ISO obeticholic acid results in increased expression of LENG8 mRNA CTD PMID:27939613 NCBI chr 1:70,040,785...70,052,662
Ensembl chr 1:70,040,785...70,052,488 		JBrowse link
G Lgi4 leucine-rich repeat LGI family, member 4 increases expression ISO obeticholic acid results in increased expression of LGI4 mRNA CTD PMID:27939613 NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874 		JBrowse link
G Lime1 Lck interacting transmembrane adaptor 1 decreases expression ISO obeticholic acid results in decreased expression of LIME1 mRNA CTD PMID:27939613 NCBI chr 3:168,490,535...168,496,627
Ensembl chr 3:168,490,074...168,493,127 		JBrowse link
G Lipc lipase C, hepatic type decreases expression ISO obeticholic acid results in decreased expression of LIPC mRNA CTD PMID:27939613 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Lpin1 lipin 1 decreases expression ISO obeticholic acid results in decreased expression of LPIN1 mRNA CTD PMID:27939613 NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097 		JBrowse link
G Lpin2 lipin 2 decreases expression ISO obeticholic acid results in decreased expression of LPIN2 mRNA CTD PMID:27939613 NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193 		JBrowse link
G Lss lanosterol synthase decreases expression ISO obeticholic acid results in decreased expression of LSS mRNA CTD PMID:27939613 NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762 		JBrowse link
G Maf MAF bZIP transcription factor increases expression ISO obeticholic acid results in increased expression of MAF mRNA CTD PMID:27939613 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F increases expression ISO obeticholic acid results in increased expression of MAFF mRNA CTD PMID:27939613 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in decreased expression of MAP1LC3B protein] CTD PMID:26655953 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k3 mitogen activated protein kinase kinase 3 decreases expression ISO obeticholic acid results in decreased expression of MAP2K3 mRNA CTD PMID:27939613 NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO obeticholic acid results in decreased expression of MAP2K6 mRNA CTD PMID:27939613 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map2k7 mitogen activated protein kinase kinase 7 decreases expression ISO obeticholic acid results in decreased expression of MAP2K7 mRNA CTD PMID:27939613 NCBI chr12:2,591,312...2,600,534
Ensembl chr12:2,591,219...2,604,222 		JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 decreases expression ISO obeticholic acid results in decreased expression of MAP3K14 mRNA CTD PMID:27939613 NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 decreases expression ISO obeticholic acid results in decreased expression of MAP3K5 mRNA CTD PMID:27939613 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 increases expression ISO obeticholic acid results in increased expression of MAP3K8 mRNA CTD PMID:27939613 NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of MAPK1 protein] CTD PMID:27865854 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk11 mitogen-activated protein kinase 11 decreases expression ISO obeticholic acid results in decreased expression of MAPK11 mRNA CTD PMID:27939613 NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 decreases expression ISO obeticholic acid results in decreased expression of MAPK12 mRNA CTD PMID:27939613 NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of MAPK3 protein] CTD PMID:27865854 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mdh1 malate dehydrogenase 1 increases expression ISO obeticholic acid results in increased expression of MDH1 mRNA CTD PMID:27939613 NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator decreases expression ISO obeticholic acid results in decreased expression of METRNL mRNA CTD PMID:27939613 NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869